Ademuyiwa, Foluso O. http://orcid.org/0000-0002-6766-2258
Salyer, Patricia
Ma, Yinjiao
Fisher, Sherri
Colditz, Graham
Weilbaecher, Katherine
Bierut, Laura J.
Article History
Received: 17 May 2019
Accepted: 12 July 2019
First Online: 19 July 2019
Compliance with ethical standards
:
: Foluso Ademuyiwa has served as an advisory board member for Eisai, Astra Zeneca, Jounce, Immunomedics, and QED Therapeutics. Foluso Ademuyiwa performs consulting for Cardinal Health, Best Doctors, Advance Medical Inc. Foluso Ademuyiwa has received institutional research funding from Polyphor, Pfizer, RNA Diagnostics, Immunomedics, Abbvie, and Seattle Genetics. Laura J. Bierut is listed as an inventor on Issued U.S. Patent 8,080,371,“Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Patricia Salyer, Yinjiao Ma, Sherri Fisher, Graham Colditz, and Katherine Weilbaecher declare that they have no conflict of interest.
: This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.